List view / Grid view
21 November 2024 | By Steffanie Wilson
In this article, Steffanie Wilson, Vice President and Neuroscience Therapeutic Area Lead, Emmes Group, discusses the future of psychedelic research and highlights the impact of the FDA’s decision on Lykos Therapeutics’ NDA for its MDMA therapy to treat PTSD.
12 August 2016 | By Niamh Louise Marriott, Digital Content Producer
Searching for answers through a series of biochemical tests, the scientists discovered that the patient had a cerebrospinal fluid deficiency in biopterin, a protein involved in the synthesis of several brain signalling chemicals called neurotransmitters. After receiving an analogue of biopterin to correct the deficiency, the patient's depression symptoms largely…
21 June 2021 | By Hannah Balfour (European Pharmaceutical Review)
The Canadian Government is funding studies to establish ketamine as a safe and effective treatment for patients with bipolar depression.
4 November 2022 | By Catherine Eckford (European Pharmaceutical Review)
According to a new study, 25mg of psilocybin alongside psychological support, greatly reduces symptoms in participants with treatment-resistant depression.
7 August 2023 | By Catherine Eckford (European Pharmaceutical Review)
The first approved oral treatment that provides rapid symptomatic improvement in postpartum depression (PPD) is expected to be commercially available in the fourth quarter of 2023.
15 December 2022 | By Guy Goodwin (COMPASS Pathways)
There is growing interest in the use of psychedelic-assisted therapy for treatment of mental health conditions. Here, Guy Goodwin, Chief Medical Officer of COMPASS Pathways, explores the potential of tryptamines to treat depression, sharing results from a recent clinical trial.
9 April 2018 | By European Pharmaceutical Review
New research points to the important role that benzodiazepines may have in depression...
5 January 2017 | By Niamh Marriott, Digital Editor
Amorsa has announced a research, option and license agreement with Janssen to develop and commercialise a novel small molecule drug candidate for depression...
10 November 2021 | By Anna Begley (European Pharmaceutical Review)
COMP360 25mg versus 1mg comparator dose demonstrated a -6.6 point difference on the Montgomery-Åsberg Depression Rating Scale by week 3.
29 September 2022 | By Catherine Eckford (European Pharmaceutical Review)
Data demonstrated that a one-time injection of the drug BRII-296 is safe and effective for most patients with postpartum depression (PPD).
10 October 2023 | By Catherine Eckford (European Pharmaceutical Review)
New safety data for a Phase IIIb study in treatment-resistant depression (TRD), revealed at ECNC 2023, showed that esketamine NS significantly increased the proportion of patients achieving remission compared to quetiapine XR.
22 April 2015 | By Victoria White
Bionomics has initiated a Phase II clinical study of BNC210, the Company’s drug candidate in development for the treatment of anxiety and depression...
1 July 2015 | By Victoria White
St John’s Wort, a herbal medicine used in the treatment of depression, has been found to cause the same adverse reactions as prescription antidepressants...
28 November 2022 | By Catherine Eckford (European Pharmaceutical Review)
SPRAVATO® nasal spray helped treatment-resistant depression patients remain remission and relapse free in a Phase III trial.
11 April 2024 | By Catherine Eckford (European Pharmaceutical Review)
Research suggests that for every five mothers given low dose esketamine, one major depressive episode could be prevented.
